Citations

Clear

3042 citation(s) found for "Kumar, S".

A Small Molecule Antagonist Inhibits Thyrotropin Receptor Antibody-Induced Orbital Fibroblast Functions Involved in the Pathogenesis of Graves Ophthalmopathy
Kumar, Seema , Neumann, Susanne , Coenen, Michael J., Chiriboga, Pamela, Gershengorn, Marvin C. , Bahn, Rebecca S. , Turcu, Adina F. , Iyer, Seethalakshmi

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 13, 2013 | Volume: 98 | Issue: 5 | Pages: 2153-2159

10.1210/jc.2013-1149 | PMID 23482611 Get It

Meta‐analysis: serological markers and the risk of acute and chronic pouchitis
Singh, Siddharth , Sharma, Piyush Kumar , Loftus, Edward V. , Pardi, Darrell S. , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 12, 2013 | Volume: 37 | Issue: 9 | Pages: 867-875

10.1111/apt.12274 | PMID 23480145 Get It

Summary Background Serological markers such as anti‐neutrophil cytoplasmic antibody ( ANCA ) and anti‐ S accharomyces cerevisiae antibody ( ASCA ) may be associated with pouchitis after ileal pouch‐anal anastomosis ( IPAA ). Aim To perform a systematic review with meta‐analysis of studies evaluating the association of ANCA and ASCA status with risk of acute and chronic pouchitis after IPAA . Methods We searched multiple databases (upto S eptember 2012) for studies reporting ANCA and/or ASCA status along with risk of acute or chronic pouchitis after IPAA in adults with ulcerative colitis ( UC ). We abstracted odds ratio ( OR ) or raw data from the individual studies to calculate summary OR estimates with 95% CI s using random‐effects model. Results Eight studies reporting 184 cases of acute pouchitis and six studies reporting 151 cases of chronic pouchitis were included. The odds of chronic pouchitis were 76% higher in ANCA ‐positive patients than ANCA ‐negative (six studies; OR : 1.76; 95% CI : 1.19–2.61; P < 0.01). ASCA‐positivity was not associated with the risk of chronic pouchitis (three studies; OR : 0.89; 95% CI : 0.49–1.59; P = 0.68). Neither ANCA (eight studies; OR : 1.54; 95% CI : 0.79–3.02; P = 0.21) nor ASCA ‐positivity (two studies; OR : 1.28; 95% CI : 0.25–6.54; P = 0.77) were associated with the risk of acute pouchitis. Conclusions The risk of chronic pouchitis after IPAA is higher in ANCA ‐positive patients, but the risk of acute pouchitis is unaffected by ANCA status. ASCA status was not associated with the risk of acute or chronic pouchitis. This information may be used to counsel UC patients regarding their risk of pouchitis after IPAA .
Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
Painuly, Utkarsh , Kumar, Shaji

Mayo Clinic

Clinical Medicine Insights: Oncology | February 28, 2013 | Volume: 7 | Issue: No issue available | Pages: No page available

10.4137/cmo.s7764 | PMID 23492937 Get It

Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibility to apoptosis. Bortezomib, in particular has shown significant clinical efficacy in myeloma treatment. It is the most commonly used proteasome inhibitor and has been tested to be effective in prolonging the overall survival in several trials. Its combinations with cyclophosphamide and dexamethasone are the treatment of choice for standard risk patients following the mSMART guidelines. The success with its lower dosage in elderly and its proven efficacious subcutaneous usage makes Bortezomib a useful agent for maximizing patient compliance and minimizing therapy related toxicity and costs. This review discusses several trials where Bortezomib has been used as a single/combination agent for front-line treatment of multiple myeloma.
The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria
(ITR‐ICBD), International Team for the Revision of the International Criteria for Behçet's Disease, Davatchi, Fereydoun , Assaad‐Khalil, Samir H. , Calamia, Kenneth , Sadeghi‐Abdollahi, Bahar, Schirmer, Michael , Tzellos, Thrasyvoulos , Zouboulis, Christos C. , Akhlagi, Massoomeh, Aldalaan, Abdullah M. , Alekberova, Z S , Altenburg, Andreas, Arromdee, Emvalee, Baltaci, M. , Benamour, S., Ghorbel, I. Ben, Boyvat, Ayşe , Carvalho, Luísa , Chen, W., Ben‐Chetrit, Eldad , Chams‐Davatchi, C., Correia, João , Crespo, Jorge , Dong, Yanqing , Paixão‐Duarte, F., Elmuntaser, K., Elonakov, A. V., Gil, Juca , Hayani, R.M., Houman, H., Isayeva, Ayat R., Jamshidi, Ahmadreza , Kaklamanis, P., Kumar, Anjali S. , Kyrgidis, Αthanassios , Madanat, W. , Nadji, Abdolhadi, Namba, Kenichi , Ohno, Shigeaki , Olivieri, Ilaria , Patto, José Vaz , Pipitone, Nicolò , Queiroz, Marisa Vieira de , Ramos, F., Resende, Carlos Xavier , Rosa, C. M., Salvarani, Carlo , Serra, Mauricio, Shahram, Farhad , Shams, H, Sharquie, Khalifa E. , Sliti‐Khanfir, M., Abreu, T. Tribolet de, Vasconcelos, Carlos , Vedes, Joana, Wechsler, B., Cheng, Y.K., Zhang, Z. , Ziaei, Naghmeh, (ITR‐ICBD), International Team for the Revision of the International Criteria for Behçet's Disease, Crook, Julia E. , Ali, Asad Abu Bakar , Bastos, Marcus Gomes , Dias, Cláudia Camila , Haghdoost, Ali Akbar , Ramos, F., Salvarani, Carlo , Abreu, T. Tribolet de, Cheng, Y.K., Kyrgidis, Athanassios , Zouboulis, Christos C

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | February 26, 2013 | Volume: 28 | Issue: 3 | Pages: 338-347

10.1111/jdv.12107 | PMID 23441863 Get It

Abstract Objective Behçet's disease ( BD ) is a chronic, relapsing, inflammatory vascular disease with no pathognomonic test. Low sensitivity of the currently applied International Study Group ( ISG ) clinical diagnostic criteria led to their reassessment. Methods An International Team for the Revision of the International Criteria for BD (from 27 countries) submitted data from 2556 clinically diagnosed BD patients and 1163 controls with BD ‐mimicking diseases or presenting at least one major BD sign. These were randomly divided into training and validation sets. Logistic regression, ‘leave‐one‐country‐out’ cross‐validation and clinical judgement were employed to develop new International Criteria for BD ( ICBD ) with the training data. Existing and new criteria were tested for their performance in the validation set. Results For the ICBD , ocular lesions, oral aphthosis and genital aphthosis are each assigned 2 points, while skin lesions, central nervous system involvement and vascular manifestations 1 point each. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having BD . In the training set, 93.9% sensitivity and 92.1% specificity were assessed compared with 81.2% sensitivity and 95.9% specificity for the ISG criteria. In the validation set, ICBD demonstrated an unbiased estimate of sensitivity of 94.8% (95% CI : 93.4–95.9%), considerably higher than that of the ISG criteria (85.0%). Specificity (90.5%, 95% CI : 87.9–92.8%) was lower than that of the ISG ‐criteria (96.0%), yet still reasonably high. For countries with at least 90%‐of‐cases and controls having a pathergy test, adding 1 point for pathergy test increased the estimate of sensitivity from 95.5% to 98.5%, while barely reducing specificity from 92.1% to 91.6%. Conclusion The new proposed criteria derived from multinational data exhibits much improved sensitivity over the ISG criteria while maintaining reasonable specificity. It is proposed that the ICBD criteria to be adopted both as a guide for diagnosis and classification of BD .
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
Kourelis, Taxiarchis , Lacy, Martha Q. , Kyle, Robert A. , Kapoor, Prashant , Zeldenrust, Steven R., Hayman, Suzanne R. , Lust, John A., Russell, Stephen J. , Lin, Yi , Rajkumar, S. Vincent , Kumar, Shaji , Leung, Nelson , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Zent, Clive S. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | February 12, 2013 | Volume: 88 | Issue: 5 | Pages: 375-378

10.1002/ajh.23413 | PMID 23508840 Get It

To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non‐AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non‐AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non‐AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non‐AL is nearly as common. Distinguishing between these two groups is essential since patients with non‐AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis. Am. J. Hematol. 88:375–378, 2013. © 2013 Wiley Periodicals, Inc.
H/D Exchange Centroid Monitoring is Insufficient to Show Differences in the Behavior of Protein States
Zhang, Jun , Ramachandran, Pradeep L., Kumar, Rajiv , Gross, Michael L. , Kumar, Rajiv

Mayo Clinic

Journal of the American Society for Mass Spectrometry | February 8, 2013 | Volume: 24 | Issue: 3 | Pages: 450-453

10.1007/s13361-012-0555-z | PMID 23397137 Get It

Catatonic Disorder Due to a General Medical or Psychiatric Condition
Smith, Vanessa D., Philbrick, Kemuel L. , Smith, Jonathan H. , Kumar, Neeraj

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | February 8, 2013 | Volume: 24 | Issue: 2 | Pages: 198-207

10.1176/appi.neuropsych.11060120 | PMID 22772668 Get It

Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer
Isham, Crescent R., Bossou, Ayoko R., Negron, Vivian , Fisher, Kelly E., Marlow, Laura A. , Lingle, Wilma L., Smallridge, Robert C., Sherman, Eric J. , Copland, John A. , Bible, Keith C. , Kumar, Rakesh , Suman, Vera J. , Marlow, Laura

Mayo Clinic

Science Translational Medicine | January 2, 2013 | Volume: 5 | Issue: 166 | Pages: No page available

10.1126/scitranslmed.3004358 | PMID 23283368 Get It

Pazopanib and paclitaxel produce cytotoxic synergy in thyroid cancer models through inhibition of aurora kinase A.
Adult-onset autosomal dominant leukodystrophy presenting with REM sleep behavior disorder
Flanagan, Eoin P. , Gavrilova, Ralitza H. , Kumar, Neeraj , Jelsing, Elena J., Silber, Michael H. , Boeve, Bradley F. , Flanagan, E P

Mayo Clinic

Neurology | December 14, 2012 | Volume: 80 | Issue: 1 | Pages: 118-120

10.1212/wnl.0b013e31827b1b2a | PMID 23243074 Get It

Neurotoxicology
Tormoehlen, Laura M. , Kumar, Neeraj

Mayo Clinic

Neurology Clinical Practice | December 10, 2012 | Volume: 2 | Issue: 4 | Pages: 301-310

10.1212/cpj.0b013e318278be1e | PMID 30123682 Get It